Ocugen (BUL:2H51) - Stock Price, News & Analysis

2H51 Stock Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.

About the company

2H51 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

+ 1 more risk

Ocugen, Inc. Competitors

Design Therapeutics

NasdaqGS:DSGN

US$258.2m

KalVista Pharmaceuticals

NasdaqGM:KALV

US$509.6m

Xspray Pharma

OM:XSPRAY

kr1.3b

Acumen Pharmaceuticals

NasdaqGS:ABOS

US$201.9m

Price History & Performance

Summary of all time highs, changes and price drops for Ocugen
Historical stock prices
Current Share Price	US$0.35
52 Week High	US$0.35
52 Week Low	US$0.35
Beta	3.56
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-65.59%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-93.48%

Recent updates

Shareholder Returns

	2H51	BG Biotechs	BG Market
7D	0%	0%	0%
1Y	-65.6%	0%	0%

Return vs Industry: 2H51 underperformed the BG Biotechs industry which returned -8.1% over the past year.

Return vs Market: 2H51 underperformed the BG Market which returned 11.5% over the past year.

Price Volatility

Is 2H51's price volatile compared to industry and market?
2H51 volatility
2H51 Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BG Market	0%
10% least volatile stocks in BG Market	0%

Stable Share Price: 2H51 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2H51's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	84	Shankar Musunuri	www.ocugen.com

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market.

Ocugen, Inc. Fundamentals Summary

How do Ocugen's earnings and revenue compare to its market cap?
2H51 fundamental statistics
Market cap	€234.13m
Earnings (TTM)	-€69.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.4x

P/E Ratio

Is 2H51 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2H51 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$47.28m
Gross Profit	-US$47.28m
Other Expenses	US$28.24m
Earnings	-US$75.52m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.29
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	4.7%

How did 2H51 perform over the long term?

See historical performance and comparison

2H51 Stock Overview

Rewards

Risk Analysis

Ocugen, Inc. Competitors

NasdaqGS:DSGN

US$258.2m

NasdaqGM:KALV

US$509.6m

OM:XSPRAY

kr1.3b

NasdaqGS:ABOS

US$201.9m

Price History & Performance

Recent News & Updates

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Recent updates

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer

Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request

Forecast breakeven date pushed back to 2023

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).

Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory University

Ocugen, Inc. Announces COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine

Ocugen, Inc. announces New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

High number of new and inexperienced directors